Anti-amyloidogenic indolizino[3, 2-c]quinolines as imaging probes differentiating dense-core, diffuse, and coronal plaques of amyloid-β. Issue 11 (11th October 2021)

• Record Type: Journal Article
• Authors: Kim, Kyeonghwan; Lee, Jeong Hwa; Kim, Sunmi; Lee, Songmin; Lee, Donghee; Kim, Hye Yun; Kim, Ikyon; Kim, YoungSoo
• Is Part Of: RSC medicinal chemistry. Volume 12:Issue 11(2021)
• Page Start: 1926
• Page End: 1934
• Publication Date: 2021-10-11
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1039/d1md00030f
• Languages: English
• ISSNs: 2632-8682

Abstract

Abstract : Indolizino[3, 2- c ]quinoline derivatives are potential imaging agents targeting various forms of amyloid-β plaques. Abstract : Abnormal deposition of amyloid-β (Aβ) is a major biomarker that is often used to diagnose Alzheimer's disease (AD). The Aβ plaque levels in the cortex and hippocampus are measured by either brain histology or positron emission tomography. Although cerebral plaques are found in several phenotypes, such as dense-core, diffuse, and coronal, imaging probes differentiating these plaques are currently unavailable. Here, we report that fluorescent indolizino[3, 2- c ]quinoline derivatives (YIQ ) distinguish Aβ plaque phenotypes in brains of 5XFAD Alzheimer transgenic mice. We synthesized and screened 64 YIQ compounds through a series of in vitro and ex vivo Aβ staining assays. We found 20 compounds that could stain the Aβ phenotypes, 10 for dense-core plaques, eight for both dense-core and diffuse plaques, and two for solely visualizing only the coronal plaques while leaving the centric core unstained. Among the 20 imaging candidates, five YIQ s displaying anti-Aβ aggregation efficacy were confirmed by thioflavin T assays and electrophoretic analyses.